Bod Australia (ASX:BDA) - CEO, Jo Patterson
CEO, Jo Patterson
Source: InvestorStream
The Market Herald - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Bod Australia (BDA) announced filling 755 MediCabilis prescriptions in October – a 106 per cent increase in monthly prescription volumes since July last year
  • Since January, the medicinal cannabis company has filled 4400 prescriptions which marks a 124 per cent increase on total volumes for last year
  • Bod is highly encouraged by the ongoing sales momentum and expects this growth to continue
  • Bod ended the day 4.08 per cent in the green to close for 51 cents

Bod Australia (BDA) has announced it filled 755 MediCabilis prescriptions during the month of October.

The medicinal cannabis product is being prescribed for a variety of conditions and Bod now has a 57 per cent share in the Australian CBD market.

October prescription volumes outline a 106 per cent increase on the average monthly prescription volumes since July 2019.

Bod has now filled 4400 prescriptions since January this year, which marks a 124 per cent increase on last year’s total volumes of 1959 prescriptions.

“It is pleasing to see the continued growth and support for our medical cannabis product, MediCabilis,” CEO Jo Patterson said.

A further testament to Bod’s presence in the highly-competitive CBD market is that repeat prescriptions for October accounted for 60 per cent of the month’s total prescriptions. This shows that patients and physicians are satisfied with the product.

“Strong demand for our MediCabilis product range in Australia will continue to add to our growing revenue profile and we are confident that sales will continue to increase. I look forward to updating shareholders on sales achievements across the coming months,” Jo concluded.

Bod ended the day 4.08 per cent in the green to close for 51 cents.

BDA by the numbers
More From The Market Herald
Imugene (ASX:IMU) - Managing Director & CEO, Leslie Chong

Imugene set to secure European patent for cancer vaccine; announces new phase II CRC cancer trial in 2024

Imugene (ASX:IMU) is on the verge of securing approval from the European Patent Office (EPO) for…

The Calmer Co locks in $700k in funding via convertible note issue

The Calmer Co (ASX:CCO) has confirmed its receipt of $700,000 in funding from existing shareholders.

FDA greenlights Botanix Pharmaceuticals’ Sofdra resubmission plan

FDA approves Botanix's strategy for Sofdra NDA resubmission with no additional materials requested, keeping submission to…

Botanix Pharmaceuticals successfully closes $13.5m Placement to boost US commercial activities

Botanix Pharmaceuticals (ASX: BOT) has closed its $13.5 million placement to both new and existing institutional…